| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,955,918 | -2,670,705 |
| Depreciation and amortization | 3,691,435 | 2,455,796 |
| Stock compensation | 831,823 | 544,376 |
| Gain on sale of real estate assets, net | 5,078,302 | 4,777,327 |
| Net loss (gain) in fair value marketable securities-Conduit Pharmaceuticals Inc | -184,672 | -184,459 |
| Net loss (gain) in fair value marketable securities-All Other Than Conduit | 0 | 0 |
| Impairment of goodwill and real estate assets | 4,427,245 | 4,344,332 |
| Amortization of financing costs | 201,500 | 137,749 |
| Amortization of below-market leases | 3,509 | 2,266 |
| Straight-line rent adjustment | 41,733 | -27,948 |
| Other assets | -294,586 | -36,322 |
| Accounts payable and accrued liabilities | -500,641 | -397,856 |
| Accrued real estate taxes | -514,848 | -839,159 |
| Net cash used in operating activities | -380,224 | -1,012,227 |
| Real estate acquisitions | 9,444,465 | 9,444,465 |
| Additions to buildings and tenant improvements | 2,178,973 | 741,071 |
| Proceeds from sale of marketable securities | 13,990 | 13,990 |
| Proceeds from sales of real estate, net | 23,043,395 | 21,544,343 |
| Net cash provided by investing activities | 11,433,947 | 11,372,797 |
| Proceeds from mortgage notes payable, net of issuance costs | 18,942,396 | 6,592,396 |
| Payment of debt issuance costs | 333,838 | 247,882 |
| Repayment of mortgage notes payable | 27,142,992 | 14,014,678 |
| Issuance of series d preferred stock, net of offering costs | - | 0 |
| Payment of deferred offering costs | 79,170 | 0 |
| Distributions to noncontrolling interests | 507,435 | 433,804 |
| Contributions from noncontrolling interests | 0 | 0 |
| Issuance of series a common stock, net of offering costs-Common Class A | 1,671,463 | - |
| Issuance of series a common stock, net of offering costs-Series DPreferred Stock | 0 | - |
| Repurchase of series a common stock, at cost-Common Class A | 1,585,091 | 1,526,551 |
| Repurchase of series d preferred stock, at cost-Series DPreferred Stock | 327,787 | 327,787 |
| Dividends paid to series d preferred stockholders | 1,724,850 | 1,153,671 |
| Net cash used in financing activities | -11,087,304 | -11,111,977 |
| Net (decrease) increase in cash equivalents and restricted cash | -33,581 | -751,407 |
| Cash and cash equivalents at beginning of period | 8,036,496 | - |
| Cash and cash equivalents at end of period | 8,002,915 | - |
Presidio Property Trust, Inc. (SQFT)
Presidio Property Trust, Inc. (SQFT)